RT Journal Article
SR Electronic
T1 Convalescent plasma as potential therapy for severe COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20184390
DO 10.1101/2020.09.01.20184390
A1 Valentini, Ricardo
A1 Fernández, José
A1 Riveros, Dardo
A1 Pálizas, Fernando
A1 Solimano, Jorge
A1 Saúl, Pablo
A1 Medina, Juan
A1 Falasco, Viviana
A1 Dupont, María Laura
A1 Laviano, Julia
A1 Fornillo, Florencia
A1 Maymó, Daniela
A1 Gotta, Daniel
A1 Martinez, Alfredo
A1 Bonvehí, Pablo
A1 Dupont, Juan
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.01.20184390.abstract
AB At the beginning of the COVID-19 pandemic, there was high mortality and a lack of effective treatment for critically ill patients. Build on the experience in argentine hemorrhagic fever with convalescent plasma, we incorporated 90 patients into a multicenter study, and 87 were evaluable. We collected 397 donations from 278 convalescent donors. Patients received plasma with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective. 77% were male, age 54 ± 15.6 y/o (range 27-85); body mass index 29.7 ± 4,4; hypertension 39% and diabetes 20%; 19.5% had an immunosuppression condition; 23% were healthcare workers. Plasma was administered to 55 patients (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and 32 patients (37%) were infused on mechanical ventilation. The 28-day survival rate was 80%, with 91% in patients infused on spontaneous breathing and 63% in those infused on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia clinical scale at 7 and 14 days, and in PaO2 / FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation, and are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04535063Funding Statementnon fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COMITE DE ETICA EN INVESTIGACION, CEMIC (CENTRO DE EDUCACION MEDICA E INVESTIGACIONES CLINICAS) Protocol Code: CEM-COV-19-01All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthere are no supplementary materials